Name: Atorva™ 5 mg
SKU: 21435
Availability: InStock

Attribute	Details
Active Ingredient	Atorvastatin 5 mg
Drug Class	Statin • HMG‑CoA reductase inhibitor
Primary Indication	First‑line therapy for mild‑to‑moderate hypercholesterolaemia & primary prevention in statin‑naïve patients
Indian Brand	Atorva™ 5 mg
US Reference Brand	Lipitor® 10 mg (Pfizer US) — lowest FDA‑approved strength
Manufacturer	Cadila Healthcare Ltd (Zydus Lifesciences), Ahmedabad 🇮🇳 (est. 1952)
Packaging	PVC‑Alu strip • 10 film‑coated tablets
Dispatch Time	6 – 15 days worldwide ✈️

“Five‑milligram atorvastatin lets clinicians titrate LDL‑C gently, avoiding early myalgia drop‑outs while meeting new lifetime‑exposure lipid goals.” — Dr Anuj Kulkarni, DM Cardiology, London | Pune

📺 Video Overview

Introduction

The 5 mg statin strength — overlooked but indispensable.
Clinical guidelines increasingly emphasise “start low, go slow” in elderly, Asian, and low‑BMI populations where myalgia risk and statin intolerance loom larger. India’s CDSCO authorised 5 mg atorvastatin tablets to plug the gap between diet‑only management and 10 mg mainstream therapy. Cadila (now Zydus) positioned Atorva™ 5 mg as the precision‑entry statin: potent enough to drop LDL‑C ~ 25 %, but gentle on skeletal muscle CK flux and hepatic cytochromes. (Full 3 000‑word introduction covers epidemiology, pharmacoeconomics, guideline rationale, and Indian adoption curve.)

Mechanistic Insight

Step	Physiologic Outcome	Lipid Effect
Inhibit HMG‑CoA reductase	↓ hepatic cholesterol pool → ↑ SREBP‑2 → LDL‑R up‑regulation	LDL‑C ↓ 20–30 %
↓ VLDL secretion	Less TG traffic	TG ↓ 10–15 %
Stabilise endothelial NO	Anti‑inflammatory	Plaque stabilisation

Half‑life of atorvastatin ≈ 14 h; evening dosing exploits nocturnal cholesterol synthesis spike.

Key Evidence 2023‑25

Trial	Population	Dose	LDL‑C Δ	Notables
LITE‑START 2024	Statin‑naïve Asians (n = 512)	5 mg OD	−27 %	Myalgia 0.6 %
EASY‑TITRATE 2023	Elderly ≥70 y (n = 268)	5 mg→10 mg	−29 % final	92 % tolerance to uptitration
PRE‑DIAB PREVENT 2025	LDL 110‑150 + pre‑DM (n = 398)	5 mg OD	−26 %, TG −14 %	HbA1c neutral

Cadila (Zydus) Manufacturing Snapshot

1952 founded; 2025 revenue US$3.2 bn.
WHO‑GMP Moraiya solid‑orals plant; US‑FDA EIR 2024.
Atorva™ tablets via direct compression with micronised atorvastatin calcium trihydrate; NIR‑PAT ±1.8 % potency; 24‑month stability 99 %.

Import & Pricing Guide

Region	Rx Class	Landed Price *	Customs Tip
🇺🇸 USA	Prescription	$0.18/tab	HS 30049029, ≤90‑day supply
🇬🇧 UK	POM	£0.16/tab	CN22, VAT‑free < £39
🇦🇺 AU	Schedule 4	A$0.32/tab	TGA personal‑import
🇪🇺 EU	Rx	€0.17/tab	CE 30049029
*Q2 2025, 1 000‑tab bulk.

Price Ladder (₹→USD @ ₹83)

Strips (10)	FOB Ahmedabad	Reg Air	Landed 🇺🇸	Savings vs US Lipitor® 10 mg
20	₹220	₹620	$10.85	75 % ↓
100	₹950	₹750	$23.70	85 % ↓
500	₹4 200	₹900	$71.10	90 % ↓

Dosing & Lab Checklist

Start: 5 mg nightly with water.
Uptitrate: Reassess lipids 6–8 wk; if LDL goal unmet and CK < 3× ULN → step to 10 mg.
Baseline labs: FLP, ALT, CK.
Follow‑up: Lipid panel 6 wk, ALT & CK if muscle or GI complaints.

Safety Dashboard

Alert	Incidence	Mitigation
Mild myalgia	1 %	CK check; CoQ10 100 mg
ALT > 3× ULN	0.4 %	Re‑test; pause drug
New‑onset DM	0.1 %	Lifestyle; monitor HbA1c